<DOC>
	<DOCNO>NCT00150020</DOCNO>
	<brief_summary>The aim study evaluate safety tolerability EC-MPS maintenance renal transplant patient experience gastrointestinal ( GI ) intolerance due adverse event associate mycophenolate mofetil ( MMF ) convert EC-MPS .</brief_summary>
	<brief_title>Safety Tolerability Enteric-Coated Mycophenolate Sodium ( EC-MPS ) Renal Transplant Patients With GI Intolerance</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Males female age 1875 year . 2 . Recipients first secondary cadaveric , live unrelated living relate kidney transplant . 3 . Recipients least 4 week post renal transplantation . 4 . Patients currently receive MMF ( dosage allow ) , cyclosporine microemulsion , generic equivalent , cyclosporine USP ( modify ) tacrolimus without corticosteroid part immunosuppressive regimen least 2 week . 5 . Patients mild and/or moderate GI complaint ( e.g . upper abdominal pain , dyspepsia , anorexia , nausea , vomit ) without diarrhea . 1 . Multiorgan patient ( e.g . kidney pancreas ) previous transplant organ different kidney ( secondary kidney transplant allow ) . 2 . Evidence graft rejection , treatment acute rejection unstable renal function within 4 week prior baseline visit . 3 . Patients receive investigational immunosuppressive drug within 4 week prior study entry . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Renal/Kidney</keyword>
	<keyword>Transplantation</keyword>
	<keyword>MPA</keyword>
	<keyword>EC-MPS</keyword>
	<keyword>Renal Transplantation Patients GI Intolerance MMF</keyword>
</DOC>